MedPage Today) — SAN FRANCISCO — Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled with the addition of an investigational targeted therapy to standard treatment, a randomized…
Radiographic PFS in Metastatic CRPC More Than Doubles With Novel Combination

Leave a Comment Leave a Comment